PubMed Health⌕ Search

PubMed · 10959951

Atomic force microscope: a tool for studying ionophores

Abstract

The aim of the investigations was to show the analytical use of an atomic force microscopy (AFM) tip coated with an ion-selective membrane and to show that the ion-selective boundary potential is detectable as a force induced by ion-selective electrostatic interactions, which are more pronounced than double-layer forces. This new technique allows the area-specific ion exchange over boundaries to be displayed with a destruction-free technique by AFM in an aqueous buffer. From experiments with ISEs (ion-selective electrodes), a boundary potential for valinomycin was assumed to be established in close vicinity to a K+-releasing surface. To trace this boundary potential, an AFM tip was coated with a potassium-selective polymer film containing valinomycin as used in preparing ISEs. The K+-releasing substrate was prepared by incorporating a lipophilic potassium salt into a plasticized PVC layer. In contact with an electrolyte such as sodium chloride solution, an ion exchange takes place. Analogue experiments were performed using a sodium-selective ionophore, DD16C5, incorporated into the coating of the AFM tip, with a Na+-releasing substrate. The boundary potential was traced and investigated with the help of force vs distance curves. The resulting adhesion forces for a valinomycin-coated tip in a 150 mM NaCl solution were 9.8+/-3.275 nN using a blank PVC substrate and 330.15+/-113.0 nN using a substrate containing 10 wt % potassium tetrakis(4-chlorophenyl) borate. The selectivity of the ion-selective AFM tips was measured on sodium relative to potassium-releasing substrates and studied in different salt solutions with concentrations between 10 mmol L(-1) and 1 mol L(-1). For valinomycin, a force selectivity coefficient log Kf(K,Na) of -2.5+/-0.5 for K+ against Na+ and a selectivity coefficient log Kf(Na,K) of -4 +/- -0.5 for DD16C5 were measured. In addition, the surface of the polymer substrate was imaged by AFM in contact mode with and without lipophilic potassium salt. The modulation of the force-distance curves induced by the ion exchange was compared to the experimental change in elasticity of the blank and ion-exchanging substrate. The Young's moduli measured with strain force analysis on a potassium-containing substrate were 5 times smaller than the ones registered with nanoindentation and did not explain the modulation of the force vs distance curves.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Zammaretti, A Fakler, F Zaugg, UE Spichiger-Keller. 2000-08-15. Atomic force microscope: a tool for studying ionophores. https://doi.org/10.1021/ac000084u

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗